Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Morgan Goodwin is a UK-based company that pioneers the Combined Trading Platform (CTP) category, offering a comprehensive online platform for small businesses engaged in physical goods trading, along with specialized software development services, and a broad-spectrum business consultancy approach aimed at enhancing growth, efficiency, and technological advancement.
days to go:
Stretch
investment:
£788,519
Doqit offers a solution for managing life admin tasks, helping you organize important information, set action dates, and receive timely reminders, ultimately streamlining tasks like insurance renewals and warranties to reduce unnecessary expenses and simplify your life. It provides secure storage and easy access for vital information, transitioning from chaos to simplicity.
Security is also a priority for Doqit. The platform ensures that your sensitive information is stored securely, giving you peace of mind knowing that you can access your important documents and data whenever you need them, all within a few clicks.
days to go:
Extended
investment:
£87,500
UTU is a company dedicated to building the trust infrastructure for the evolving web 3.0. They aim to facilitate safer and more reliable interactions between users and platforms by utilizing a decentralized reputation and reviews protocol. This protocol involves a non-tradable reputation token (UTT) that users can stake to endorse others, leading to positive outcomes. UTU's focus initially lies in Web3 and DeFi apps, where they provide AI-powered tools to curate trust signals and help users engage confidently in various online activities. They offer a range of products, including the UTU Trust Token, Browser Extension, and Trust API/SDK, all aimed at enhancing trust and security in digital interactions.
days to go:
Extended
investment:
£150,000
Medic Bleep is a simple, secure and innovative patient-focused solution to communication challenges that healthcare professionals and the wider team in the UK National Health Service (NHS) face while going about their everyday work. It is saving each nurse & each junior doctor an estimated 48 minutes per shift. This coincides with the UK's Department of Health calling for a ban on pagers. If implemented across the NHS, it could free up the time to care for an estimated 11,000 nurses. To ensure data privacy and safety, the company allows communication to occur via the app. As a result of these safeguards and its user-friendly portal, the company's app has been downloaded 16,000 times by UK doctors and nurses. With the funds raised, the company will aim to solve looming technology gaps for over 30% of the NHS in the next 3 years and expand globally.
days to go:
Expired
investment:
£814,600
The Face Recognition Company (FRC) produces 90%+ accurate face recognition solution. In 2016, the company came up with the objective to develop the most accurate and cost-effective facial recognition solution. This technology is suitable for commercial applications or crime and other security uses. Additionally, the FRC's go-to-market strategy incorporates working through large integrators/partners/approved installers, eight of which are ready to promote and install its product to their own customer base. The FRC team has technically developed this solution by combining 100 years of experience in facial recognition. In June 2018, FRC had filed for two patents: first, ‘Recognition of 3D Objects’ and second, 'Method of and System for Recognising a Human Face’. Where suitable, FRC has also set-up an EIS tax relief.
days to go:
Expired
investment:
£215,600
Graphene Composites is a nano-materials technology company that creates the strongest, lightest, most resilient material by combining aerogel, graphene, and other nano-materials. Founded in 2016, the company, in partnerships with US/Global defence/aerospace contractor, is one of the few graphene nanotechnology companies who are developing bulletproof graphene/aerogel armour. Moreover, it is also extending its GC Shield technology to military/police applications. Besides these, GC's technology can also be used to improve the strength and reliability of wind turbines.
days to go:
Expired
investment:
£597,360
Her.9 is a Direct-To-Consumer (DTC) female technology brand that caters to the needs of women during pregnancy. It cites research arguing that up to 40% of women taking prenatal vitamins may not be able to absorb the folic acid within the UK’s leading pregnancy brand. Her.9 aims to resolve this by employing DUOCAP technology. The company asserts that DUOCAP is a capsule-in-capsule delivery system which contains solubilised prebiotics in the outer capsule and probiotics in the inner capsule. The prebiotic releases immediately and the probiotic releases later allowing for targeted supplement delivery in the body. The prenatal supplements market is set to be worth $56 billion globally by 2024. Her.9 aims to be a notable contender in this segment. The company is raising investment to build its already established partnerships and execute its marketing strategy effectively.
days to go:
Expired
investment:
£215,946
